Galectin Therapeutics (GALT) Reports Q2 Loss of $0.14/Share

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.14), versus ($0.20) reported last year.

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Union Pacific (UNP) Reiterated at Market Outperform by Citizens - Most Attractive in Rail Group
• JPMorgan Upgrades Graphic Packaging Holding Company (GPK) to Overweight